SEC Form 4 · accession 0001415889-18-000047
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank L Jaksch Jr.
Officer — CEO · Director
Period of report
Jan 10, 2018
Accepted (ET)
Jan 12, 2018 · 4:56 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 10, 2018 | M | 22,130 | $4.50 | A | 223,687 | D | |
| Common StockF2,F1 | Jan 10, 2018 | S | 22,130 | $6.52 | D | 201,557 | D | |
| Common Stock | Jan 11, 2018 | M | 6,249 | $4.50 | A | 207,806 | D | |
| Common StockF1 | Jan 11, 2018 | S | 6,249 | $6.50 | D | 201,557 | D | |
| Common Stock | holding | — | — | — | 2,075,052 | I | By Black Sheep, FLP |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy) | $4.50 | Jan 10, 2018 | M | 22,130 | D | Apr 21, 2009 | Apr 21, 2018 | Common Stock | 22,130 | 202,804 | D |
| Employee Stock Options (right to buy) | $4.50 | Jan 11, 2018 | M | 6,249 | D | Apr 21, 2009 | Apr 21, 2018 | Common Stock | 6,249 | 196,555 | D |
Explanation of responses
- F1Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted on November 17, 2017. The options exercised and sold were scheduled to expire on April 21, 2018 and Mr. Jaksch sold the shares so that the proceeds can be used to cover the exercise payment and applicable withholding taxes due.
- F2The weighted average sale price for the transaction reported was $6.52, and the range of prices were between $6.50 and $6.58. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.